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AbstrAct
Objectives Differences in terms of safety and 
efficacy of percutaneous edge-to-edge mitral repair 
between patients with functional and degenerative 
mitral regurgitation (MR) are not well established. We 
performed a systematic review and meta-analysis to 
clarify these differences.
Methods PubMed, EMBASE, Google scholar database 
and international meeting abstracts were searched for 
all studies about MitraClip. Studies with <25 patients or 
where 1-year results were not delineated between MR 
aetiology were excluded. This study is registered with 
PROSPERO.
results A total of nine studies investigating the mid-
term outcome of percutaneous edge-to-edge repair in 
patients with functional versus degenerative MR were 
included in the meta-analysis (n=2615). At 1 year, 
there were not significant differences among groups 
in terms of patients with MR grade≤2 (719/1304 vs 
295/504; 58% vs 54%; risk ratio (RR) 1.12; 95% CI: 
0.86 to 1.47; p=0.40), while there was a significantly 
lower rate of mitral valve re-intervention in patients with 
functional MR compared with those with degenerative 
MR (77/1770 vs 80/818; 4% vs 10%; RR 0.60; 95% CI: 
0.38 to 0.97; p=0.04). One-year mortality rate was 16% 
(408/2498) and similar among groups (RR 1.26; 95% 
CI: 0.90 to 1.77; p=0.18). Functional MR group showed 
significantly higher percentage of patients in New York 
Heart Association class III/IV (234/1480 vs 49/583; 
16% vs 8%; p<0.01) and re-hospitalisation for heart 
failure (137/605 vs 31/220; 23% vs 14%; p=0.03). No 
differences were found in terms of single leaflet device 
attachment (25/969 vs 20/464; 3% vs 4%; p=0.81) and 
device embolisation (no events reported in both groups) 
at 1 year.
conclusions This meta-analysis suggests that 
percutaneous edge-to-edge repair is likely to be an 
efficacious and safe option in patients with both 
functional and degenerative MR. Large, randomised 
studies are ongoing and awaited to fully assess the 
clinical impact of the procedure in these two different 
MR aetiologies.
IntrOductIOn
Mitral regurgitation (MR) affects about 10% of 
people aged more than 75 years and is the second 
most common valve disease requiring surgery in 
Europe.1 Surgical mitral valve (MV) intervention is 
currently considered the gold standard for treatment 
of symptomatic patients with severe degenerative 
MR (DMR).1 2 The role of surgery for functional 
MR (FMR) is less well defined. Nevertheless, a 
significant number of patients with symptomatic 
MR have extensive comorbidities or uncertain indi-
cations for surgery and are defined as high surgical 
risk, inoperable or not indicated for surgery, and 
approximately one-half of patients with symptom-
atic severe MR may not undergo surgery.3 The edge-
to-edge percutaneous mitral repair performed with 
the MitraClip device (Abbott Vascular, Menlo Park, 
California, USA) was reported to be safe and effec-
tive, even in high-risk patients,4 5 and it is the most 
widely catheter-based strategy used to treat MR. 
According to American Heart Association/American 
College of Cardiology guidelines, percutaneous 
edge-to-edge repair is currently recommended only 
for patients with DMR who have severe symp-
toms and are at high or prohibitive risk of surgery 
(recommendation class IIb, level of evidence B),2 
while European Society of Cardiology/European 
Association for Cardio-Thoracic Surgery guidelines 
approved it for both DMR and FMR (recommenda-
tion class IIb, level of evidence C).1 Between DMR 
(or primary) and FMR (or secondary), there are 
important differences in terms of MV morphology, 
clinical characteristics (ie, age, comorbidities), left 
ventricular (LV) function, therapies and clinical 
outcomes. In case of degenerative aetiology, MR 
is due to MV apparatus intrinsic lesions. Recovery 
of mitral competence with mitral repair abolishes 
the haemodynamic burden responsible for the dete-
rioration in LV function, may restore it if already 
depressed, and improves both quality of life and 
long-term outcome.6
In FMR, treating MR does not cure the isch-
aemic myocardial dysfunction or dilated cardio-
myopathy that caused the regurgitation in the first 
place. Thus, restoration of mitral competence in 
this setting does not correct the underlying cause of 
MR, and this may not lead to improvement in LV 
function. Moreover, it does not definitely improve 
longevity, although it improves quality of life.7 
Therefore, our aim was to systematically review 
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the published literature about percutaneous edge-to-edge repair 
outcome and perform a meta-analysis of studies investigating the 
differences after percutaneous edge-to-edge repair in these two 
very different aetiologies for which it is being applied.
MethOds
search strategy and study selection
In this study, the search strategy, study selection, data extraction 
and data analysis were performed in accordance with The 
Cochrane Collaboration and the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses guidelines.8 Meta-Anal-
yses and Systematic Reviews of Observational Studies (MOOSE) 
checklist has been followed.9
All randomised controlled trials (RCTs) and observational 
studies reporting 1-year outcome after MitraClip procedure and 
delineated between the aetiology of MR (last update 11 January 
2016) were evaluated for inclusion in the meta-analysis. We 
excluded studies with less than 25 patients, or with overlapping 
populations. Two authors (MC, CG) independently searched 
PubMed, Embase, BioMedCentral, Google Scholar and the 
Cochrane Central Register of Controlled Trials. In addition, we 
employed backward snowballing (ie, review of references from 
identified articles and pertinent reviews) and searched abstracts 
from 2014 and 2016 relevant scientific meetings (Transcatheter 
Cardiovascular Therapeutics, AHA, ACC, ESC, EuroPCR and 
PCR London Valves). The search strategy for PubMed is avail-
able as online supplementary material. This study is registered 
with PROSPERO number CRD42016048042.
data extraction
Two investigators (MC, CG) independently assessed studies for 
possible inclusion. Non-relevant articles were excluded based 
on title and abstract. Two authors (MC, AS) independently 
extracted data on study design, measurements, patient character-
istics and outcomes. Data extraction conflicts were discussed and 
resolved with another author (MP). Missing data were requested 
by means of email to the corresponding author of each study. In 
the case of studies with overlapping populations, only the manu-
script reporting the largest number of patients was selected.
Outcomes
Primary efficacy endpoints were the percentage of patients with 
MR grade ≤2 and the rate of MV re-intervention (surgical and/
or percutaneous) at 1 year. Secondary efficacy endpoints were 
the 1-year rate of overall mortality, and percentage of patients in 
New York Heart Association (NYHA) class III/IV.
Primary safety endpoints were 1-year rate of single leaflet 
device attachment (SLDA) and device embolisation.
Every endpoint was assessed according to the definitions 
reported in the original study protocols.
All analyses were performed according to the intention-to-
treat (ITT) principle. Whenever it was possible, we performed 
the analyses also considering the as-treated with follow-up popu-
lation, in order to assess consistency among ITT and as-treated 
with follow-up analyses.
statistical analysis
Continuous variables were reported as mean and SD. We 
compared the pooled baseline characteristics of both groups, 
presenting continuous variables as pooled weighted means and 
composite SD. When baseline data were available only as median 
and IQR, mean and SD were calculated.10
Pooled risk ratios (RRs) for categorical variables (dichotomous 
outcomes) were calculated using a binary random effects model, 
with the Mantel-Haenszel method.11 In studies in which no events 
were reported within groups, the difference between aetiology 
groups could not be assessed. The hypothesis of statistical hetero-
geneity was tested by means of Cochran Q statistic and I2 values. 
I² values of <40%, 40%–60% or >60% indicated low, moderate 
or substantial heterogeneity, respectively.12 Statistical tests of publi-
cation bias were not used to detect funnel-plot asymmetry because 
<10 studies were included in this study. Therefore, we visually esti-
mated funnel plots to evaluate the possibility of publication bias.13
Sensitivity and subgroup analyses were performed to assess the 
extent of which several covariates might have aﬀected the risk esti-
mates for the outcomes. 
Computation was performed with RevMan (Review Manager 
V. 5.3, The Nordic Cochrane Center, The Cochrane Collabora-
tion, Copenaghen, 2014) and Stata (V. 13.1, Stata).
results
study selection
A total of seven published articles5 14–19 and two studies presented 
at the EuroPCR 2014 and 2015 conferences20 21 were included in 
the meta-analysis. One study was a RCT,20 while the remaining 
eight studies were prospective observational registries. Figure 1 
shows the flow chart of the study selection process.
characteristics of the included studies
Two studies included patients with mixed MR aetiologies17 18: 
we excluded from the analyses 90 patients with both DMR and 
FMR aetiologies, in order to reduce confounding results. The 
main features of the included studies are summarised in table 1. 
A total of 2615 patients undergoing percutaneous edge-to-edge 
repair were analysed: 1782 patients presented with FMR and 
833 patients with DMR. For 1481 out of 2615 patients, prepro-
cedural echocardiographic assessment data regarding LVEF and 
left ventricular end diastolic volume (LVEDV) were reported in 
the included studies.
baseline patients’ features
Baseline clinical and echocardiographic features are shown 
in tables 2 and 3. Patients in the FMR group presented more 
comorbidities and the higher risk profile, while patients with 
DMR were significantly older (73±9.68 vs 78±10.55 years, 
p<0.001). No differences were found in terms of atrial fibril-
lation (54% vs 56%, FMR vs DMR, respectively, p=0.214). 
LVEDV and left ventricular end diastolic diameter (LVEDD) 
were both significantly higher in patients with FMR; in addition, 
LVEF was significantly lower in patients with FMR compared 
with those affected by DMR (38.5%±13% vs 58.3%±10.4%, 
p<0.001). There was also a significantly higher percentage of 
patients with FMR in NYHA class≥3 at baseline (86.6% vs 
75.6%, p<0.001). MR grade≥3 at baseline was present in 2088 
out of 2295 patients (91%), with a significantly lower percentage 
in patients with FMR (88.9% vs 95.2%, p<0.001).
Acute procedural success was achieved in 95% of patients, 
without differences between groups (95% vs 94%, FMR vs 
DMR, respectively, p=0.52) (online supplementary figure S1).
One-year outcome
MR grade at 1-year follow-up was reported in six out of nine 
studies, without significant differences in terms of percentage 
of patients with MR grade≤2 (RR 0.91; 95% CI: 0.76 to 1.09; 
p=0.30), with evidence of substantial heterogeneity among 
studies (I2=80%) (figure 2).
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MV re-intervention at 1 year was reported in eight out of nine 
studies, and there was a significantly lower rate in patients with 
FMR compared with those with DMR (4% vs 10%, FMR vs 
DMR, respectively; RR 0.60; 95% CI: 0.38 to 0.97; p=0.04), 
with low heterogeneity among studies (I2=33%) (figure 3).
As shown in figures 4, 1-year rate of overall mortality (reported 
in eight studies) was not significantly different between groups 
(18% vs 14%, FMR vs DMR, respectively; RR 1.26; 95% CI: 
0.90 to 1.77; p=0.18), with moderate heterogeneity between 
studies (I2=55%).
In contrast, FMR aetiology was associated with a higher 
percentage of patients in NYHA class III/IV at 1 year (14% vs 
7%, FMR vs DMR, respectively; RR 1.75; 95% CI: 1.31 to 2.36; 
p<0.001), without evidence of statistical heterogeneity among 
studies (I2=0%) (online supplementary figure S2). A significantly 
higher rate of re-hospitalisation for heart failure was reported in 
patients with FMR (RR 1.74; 95% CI: 1.05 to 2.85; p=0.03), 
with moderate heterogeneity among studies (I2=46%) (online 
supplementary figure S3).
All primary and secondary efficacy endpoints estimates 
were consistent with those assessed in the as-treated anal-
ysis (see online supplementary figures S4-S8), except for 
non-significant differences in term of MV re-intervention (4% 
vs 12%, FMR vs DMR, respectively; RR 0.61; 95% CI: 0.37 
to 1.01; p=0.06) and of re-hospitalisation for heart failure, 
and a lower grade of heterogeneity in comparison to the 
ITT analysis.
Primary safety endpoints at 1 year were reported in four out 
of nine studies. No events of device embolisation were reported 
among studies, while single leaflet device attachment was 
reported only in 45 out of 1433 patients (3%), without differ-
ences between patients with FMR and DMR (RR 0.76; 95% CI: 
0.08 to 7.28; p=0.81), and with evidence of substantial hetero-
geneity among studies (I2=78%) (figure 5).
Furthermore, we derived funnel-plot distributions of primary 
efficacy endpoints from the SE of the logRR plotted against the 
logRR confirming the absence of publication bias and small study 
effect for MV re-intervention, while there were evidence for the 
presence of small-study effects for MR grade≤2 (online supple-
mentary figures S9 and S10).
Finally, the percentage of patients with MR grade≤2 was 
consistent at sensitivity analyses performed including only 
studies with the explicit inclusion criterion of MR grade≥3 at 
baseline (RR 1.02; 95% CI: 0.91 to 1.14; p=0.74).5 16 17 21
Figure 1 Flow chart of the study selection process. ACC, American College of Cardiology; AHA, American Heart Association; ESC, European Society 
of Cardiology; MR, mitral regurgitation; TCT, Transcatheter Cardiovascular Therapeutics.
table 1 Main features of the studies included in the meta-analysis
study design
study population
Multicentric
Independent echocardiographic 
core laboratoryOverall FMr dMr
ACCESS-EU17 Prospective 510 393 117 Yes No
Braun et al. 201414 Prospective 119 47 72 No No
Chan et al. 201216 Prospective 27 12 15 No No
EVEREST II RCT20 RCT 178 48 130 Yes Yes
EVEREST II HRS5 Prospective 211 149 62 Yes Yes
EVEREST II REALISM21 Prospective 628 439 189 Yes Yes
GRASP15 Prospective 117 89 28 No No
Pilot European sentinel registry18 Prospective 595 452 143 Yes No
Rudolph et al. 201319 Prospective 230 153 77 No No
Pooled population 2615 1782 833
DMR, degenerative mitral regurgitation; EVEREST II, Endovascular Valve Edge-to-Edge Repair Study II; FMR, functional mitral regurgitation; RCT, randomised controlled trial.
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dIscussIOn
To the best of our knowledge, this is the first meta-analysis of 
prospective studies investigating the differences, in terms of 
1-year efficacy and safety, between FMR and DMR after percu-
taneous edge-to-edge mitral repair. The main findings for the 
two aetiology groups are as follows:
1. Percentages of patients with MR grade≤2 at 1 year were 
similar between FMR and DMR groups.
2. Patients with FMR had a significantly lower 1-year rate of 
MV re-intervention compared with DMR.
3. Similar rate of 1-year overall mortality was reported between 
FMR and DMR groups.
4. No differences were found in terms of 1-year single leaflet 
device attachment and device embolisation rates.
5. Conversely, a significantly higher percentage of patients 
in NYHA functional class III/IV and a higher rate of re-
hospitalisation for heart failure were reported in patients 
with FMR.
FMR and DMR are two conditions that differ each other in 
several ways. Unfortunately, only the Endovascular Valve Edge-
to-Edge Repair Study II RCT has investigated acute, mid and 
long-term outcome after the percutaneous edge-to-edge repair, 
and with more than 2/3 of patients with DMR it was not powered 
enough to assess any eventual difference due to MR aetiology.4
To fully understand the role of percutaneous MV repair, 
we evaluated the major differences reported in the present 
meta-analysis, which pooled the results of all RCT and observa-
tional studies reporting 1-year outcome after percutaneous edge-
to-edge repair according to MR aetiology.5 14–21 As expected, 
baseline features of patients affected by FMR resulted in signifi-
cantly higher cardiovascular risk profile compared with patients 
with DMR. In addition, the echocardiographic features reported 
table 2 Baseline clinical features in the studies included in the meta-analysis
study
Age (year, sd) Male (%) dM (%) cKd (%) AF (%) cAd (%) cOPd (%)
FMr dMr FMr dMr FMr dMr FMr dMr FMr dMr FMr dMr FMr dMr
ACCESS-EU 73 (9) 75.6 (12) 267 59 134 17 189 30 248 67 267 48 79 17
Braun et al. 
201414
70.7 (10) 72.2 (12) 36 44 9 7 24 14 33 36 33 30 12 11
Chan et al. 
201216
71 (14) 77 (10) 9 8 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
EVEREST II 
HRR
N/A N/A 91 37 66 19 48 17 92 42 N/A N/A N/A N/A
EVEREST II 
RCT
68 67 23 90 7 7 4 3 21 39 35 48 15 12
EVEREST II
REALISM
74 (11) 73 (9) 272 106 180 47 136 51 303 140 369 121 145 59
GRASP 72 (11) 73 (9) 59 19 35 5 36 8 36 11 50 7 21 3
Pilot 
European 
sentinel 
registry
72.8 (10) 78.3 (8) 306 75 150 18 148 35 123 72 144 37 90 29
Rudolph et 
al. 201319
73 (9) 77 (9) 109 39 57 18 96 29 93 53 111 41 35 12
Pooled 
population
73.1 (10) 78.1 (10) 1172(66) 477(57) 638(36) 138(23) 681(39) 187(23) 949 (54) 460(56) 1009(62) 332(44) 397(25) 143(19)
p Value <0.001 <0.001 <0.001 <0.001 0.214 <0.001 0.003
AF, atrial fibrillation; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; DMR, degenerative mitral 
regurgitation; EVEREST II, Endovascular Valve Edge-to-Edge Repair Study II; FMR, functional mitral regurgitation; RCT, randomised controlled trial.
table 3 Baseline NYHA class and echocardiographic features in the studies included in the meta-analysis
study
nYhA 3–4 (%) Mr grade 3–4 (%) lVeF (%) lVedV, ml lVedd, mm
FMr dMr FMr dMr FMr dMr FMr dMr FMr dMr
ACCESS-EU 84 73 98 97 N/A N/A N/A N/A N/A N/A
Braun et al. 201414 98 81 83 96 35 58 193 139 64 56
Chan et al. 201216 N/A N/A 100 100 32 46 228 156 64 57
EVEREST II RCT 65 45 100 100 48 64 N/A N/A N/A N/A
EVEREST II HRR 87 84 80 95 N/A N/A 170 137 N/A N/A
EVEREST II REALISM 86 84 78 91 42 60 162 124 58 51
GRASP 79 82 100 100 33 55 N/A N/A N/A N/A
Pilot European sentinel registry 88 77 99 100 37 59 172 119 N/A N/A
Rudolph et al. 201319 96 95 100 100 37 57 222 148 68 60
  Pooled population 87 77 89 95 39 58 178 131 61 54
p Value <0.001 <0.001 <0.001 <0.001 <0.001
DMR, degenerative mitral regurgitation; EVEREST II, Endovascular Valve Edge-to-Edge Repair Study II; FMR, functional mitral regurgitation; LVEDD, left ventricular end-diastolic 
diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart Association; RCT, randomised 
controlled trial.
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that patients with FMR were characterised by significantly lower 
LVEF and higher LVEDD and LVEDV, in agreement with under-
lying pathophysiological mechanisms of the two aetiologies.22
The presence of low LVEF due to negative LV remodelling 
makes the potential benefits of percutaneous edge-to-edge 
repair less predictable in terms of clinical and echocardiographic 
outcomes in patients with FMR.23 24 Therefore, it is important 
to remark the high percentage of patients with MR grade≤2 
reported at 1 year in our study in both groups (85% in the 
as-treated with follow-up population) without significant differ-
ences between groups. MR recurrence is frequent after surgical 
MV repair in patients with FMR, with 14%–66% of patients 
with MR grade>2 at follow-up23 25 26; conversely, surgical MV 
repair has shown durable results in patients with DMR, with a 
risk of recurrence of moderate-to-severe MR of 1%–2% only per 
year.27 Thus, our results emphasise the positive impact that the 
percutaneous edge-to-edge repair can achieve in case of FMR.28 
Indeed, the absence of severe MR recurrence, a main concern 
expected in FMR because of the progressive LV dysfunction,23 
could be considered a sign of interruption of the LV dila-
tion-MR worsening loop.24 Animal data demonstrate that reduc-
tion in MR severity to a regurgitant fraction of approximately 
one-third (moderate MR) allows for reverse remodelling and 
improved muscle function in case of LV dysfunction.29 Reverse 
LV remodelling after percutaneous edge-to-edge repair was 
reported mostly in patients with no advanced heart failure 
(LVEF>30%) and without severe LV dilation (LVEDD<70 mm, 
LVEDV<200 mL)28; reverse LV remodelling is unlikely also 
after MV surgery in case of FMR with dilated and compromised 
LV at baseline.23 Conversely, maintaining of optimal results 
at follow-up is more achievable after successful procedure in 
patients with DMR, because of less frequent LV dysfunction.30
After surgical MV repair, MV re-intervention rates reported 
in literature range between 3% and 5%, and are similarly low 
in both FMR26 and DMR.31 Therefore, an unexpected finding 
of our study was the significantly lower rate of MV re-inter-
vention reported in patients with FMR (4%) compared with 
those with DMR (10%), despite a comparable rate of SLDA 
among groups (3% vs 4%, FMR vs DMR, respectively, p=0.81), 
leading us to look for further explanation. It is reasonable to 
speculate that baseline surgical risk profile (higher in patients 
with FMR) could have limited the decision of surgical re-inter-
vention during follow-up, even when these patients had deteri-
orated, especially in those needing cardiac surgery. Indeed, in 
Figure 2 Risk estimates of MR grade≤2 for functional MR versus degenerative MR. Forest plot shows results for MR grade≤2 at 1 year. EVEREST II, 
Endovascular Valve Edge-to-Edge Repair Study II; HRR, High Risk Registry; MR, mitral regurgitation.
Figure 3 Risk estimates of MV re-intervention for functional mitral regurgitation versus degenerative mitral regurgitation. Forest plot shows results 
for MV re-intervention at 1 year. EVEREST II, Endovascular Valve Edge-to-Edge Repair Study II; MV, mitral valve.
Figure 4 Risk estimates of overall mortality for functional mitral regurgitation versus degenerative mitral regurgitation. Forest plot shows results for 
overall mortality at 1 year. EVEREST II, Endovascular Valve Edge-to-Edge Repair Study II; RCT, randomised controlled trial.
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a subanalysis on patients with FMR from the ACCESS-Europe 
A Two-Phase Observational Study of the MitraClip System in 
Europe (ACCESS-EU) registry, most of the MV re-interven-
tions performed at follow-up were reported in patients with 
LVEF>40%.32 Similar results were observed considering other 
important risk factors, such as chronic kidney disease, which was 
less frequent in those who underwent surgical re-interventions.33
Our results showed comparable overall mortality rate between 
groups (18% vs 14%, FMR vs DMR, respectively, without 
substantial heterogeneity among studies), despite the higher 
risk profile characterising patients with FMR, which predis-
poses to worse outcome in these patients compared with those 
with DMR,3 also after surgical MV repair.34 In fact, the overall 
mortality rate after surgical repair of FMR ranges from 20% 
to 50%.7 25 Conversely, long-term survival after surgical repair 
of DMR is similar to that observed in the age-matched general 
population.35 Thus, looking at data of this meta-analysis, it 
seems that the percutaneous edge-to-edge repair was selected for 
patients with FMR due to the less clear indications for surgery, 
compared with DMR where comorbidities influenced the choice 
for percutaneous edge-to-edge repair rather than surgery. We 
have to take into account that the more advanced age reported 
in patients with DMR could have counterbalanced the effects of 
other important risk factors and comorbidities present in patients 
with FMR. However, the high overall mortality rate reported in 
our meta-analysis (16%) seems to reflect the excessively high-
risk profile of treated patients, which is near to those reported 
by Goel et al in inoperable patients with MR (90% with FMR) 
treated with medical therapy alone (20% at 1 year and 50% at 
5 years).3 In the future, it could be that better patient selection 
and performing percutaneous edge-to-edge repair at earlier 
stage could avoid treatment of those patients with advanced 
LV remodelling, more than severe MR, and many comorbidi-
ties, who benefit less from the procedure. The reassuring safety 
features (only 3% of 1-year rate of SLDA, and no events of 
device embolisation reported in our analysis) and the good effi-
cacy profile of percutaneous edge-to-edge repair support the 
proposal to consider this treatment as a primary tool for patients 
with FMR and not only as a rescue therapy.
Ongoing trials, such as the A Multicenter, Randomised, Controlled 
Study to Assess Mitral vAlve reconsTrucTion for advancEd Insuf-
ficiency of Functional or iscHemic ORigiN (MATTERHORN, 
NCT02371512) RCTs, in which the percutaneous edge-to-edge 
repair is compared with surgical repair or replacement in patients 
with FMR, and the Cardiovascular Outcomes Assessment of the 
MitraClip Percutaneous Therapy for Heart Failure Patients With 
Functional Mitral Regurgitation (COAPT, NCT01626079), and 
the Multicentre Study of Percutaneous Mitral Valve Repair Mitra-
Clip Device in Patients With Severe Secondary Mitral Regurgita-
tion (MITRA-FR, NCT01920698) randomised trials, in which 
the percutaneous edge-to-edge repair is compared with optimal 
medical therapy in patients affected by FMR, should help to clarify 
the therapeutic position of percutaneous edge-to-edge repair in 
these setting of patients.
study limitations
This article represents a study-level meta-analysis; therefore, 
a relevant limitation is the lack of patient-level data. In addi-
tion, the studies included in the analysis enrolled heterogeneous 
populations, and this is likely to have contributed significantly 
to the heterogeneity observed. Moreover, there were many 
differences between the two groups in terms of baseline features 
and comorbidities, due to fundamentally different nature of the 
DMR and FMR populations. As with any meta-analysis, our 
study shares possible limitations of the included studies. More 
in detail, only one out of nine studies had a randomised design. 
Finally, we were not able to assess the impact of acute procedural 
success and of postprocedural MR grade on clinical and echocar-
diographic outcome, because the included studies did not report 
these data stratified by MR aetiology.
cOnclusIOns
Our meta-analysis suggests that percutaneous edge-to-edge repair 
appears to be a reasonable option in patients affected by both 
FMR and DMR, keeping into account the various therapeutic 
Figure 5 Risk estimates of primary safety endpoints for functional mitral regurgitation versus degenerative mitral regurgitation. Forest plot shows 
results for single leaflet device attachment at 1 year. Results of device embolisation are not shown because no events were reported among studies. 
EVEREST II, Endovascular Valve Edge-to-Edge Repair Study II; RCT, randomised controlled trial.
Key messages
What is already known on this subject?
The percutaneous edge-to-edge repair has shown to be a good 
option for high-risk patients with mitral regurgitation (MR), 
even with end-stage systolic heart failure, but there is still no 
consensus on its use in patients with functional MR (FMR) 
because of the lack of randomised studies focusing on patients 
affected by FMR not amenable to surgery.
What might this study add? 
In a meta-analysis of randomised and observational studies 
of patients affected by functional or degenerative MR (DMR) 
undergoing percutaneous edge-to-edge repair procedure, patients 
with FMR reported a lower rate of re-intervention than those 
with DMR (4% vs 10%; p=0.04) and a comparable rate of MR 
recurrence (58% vs 54%; p=0.40) and of mortality (18% vs 14%; 
p=0.18) after 1-year follow-up, despite a worse baseline risk profile.
how might this impact on clinical practice? 
The extremely reassuring safety profile and the good efficacy 
shown in this meta-analysis support the proposal to definitively 
assess if this treatment could be considered a primary tool 
for patients with FMR and not only as a rescue therapy. Large 
ongoing randomised trials are hugely awaited to conclusively 
address this issue.
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goals achievable in these two deeply different conditions. Large, 
randomised studies with extended follow-up are ongoing and 
awaited to fully assess the clinical impact of the percutaneous 
edge-to-edge repair in these two very different MR aetiologies.
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